460 related articles for article (PubMed ID: 27378659)
1. Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs.
Gori M; Volterrani M; Piepoli M; Senni M
Int J Cardiol; 2017 Jan; 226():136-140. PubMed ID: 27378659
[TBL] [Abstract][Full Text] [Related]
2. First-in-Class Composite Angiotensin Receptor-Neprilysin Inhibitors (ARNI) in Practice.
Barghash MH; Desai AS
Clin Pharmacol Ther; 2017 Aug; 102(2):265-268. PubMed ID: 28512738
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
Gori M; Senni M
Expert Rev Cardiovasc Ther; 2016; 14(2):145-53. PubMed ID: 26642078
[TBL] [Abstract][Full Text] [Related]
4. Sacubitril/Valsartan: A Novel Cardiovascular Combination Agent.
Sible AM; Nawarskas JJ; Alajajian D; Anderson JR
Cardiol Rev; 2016; 24(1):41-7. PubMed ID: 26466333
[TBL] [Abstract][Full Text] [Related]
5. Sacubitril/Valsartan (LCZ696) in Heart Failure.
Khder Y; Shi V; McMurray JJV; Lefkowitz MP
Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
[TBL] [Abstract][Full Text] [Related]
6. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Macdonald PS
Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
[TBL] [Abstract][Full Text] [Related]
7. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
8. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction.
Voors AA; Gori M; Liu LC; Claggett B; Zile MR; Pieske B; McMurray JJ; Packer M; Shi V; Lefkowitz MP; Solomon SD;
Eur J Heart Fail; 2015 May; 17(5):510-7. PubMed ID: 25657064
[TBL] [Abstract][Full Text] [Related]
9. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
[TBL] [Abstract][Full Text] [Related]
10. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696.
Jhund PS; Claggett BL; Voors AA; Zile MR; Packer M; Pieske BM; Kraigher-Krainer E; Shah AM; Prescott MF; Shi V; Lefkowitz M; McMurray JJ; Solomon SD;
Circ Heart Fail; 2014 Nov; 7(6):953-9. PubMed ID: 25277997
[TBL] [Abstract][Full Text] [Related]
11. Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
King JB; Bress AP; Reese AD; Munger MA
Pharmacotherapy; 2015 Sep; 35(9):823-37. PubMed ID: 26406774
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-Neprilysin Inhibition as a Paradigm for All?
Vaduganathan M; Desai AS
Curr Cardiol Rep; 2016 Nov; 18(11):115. PubMed ID: 27747488
[TBL] [Abstract][Full Text] [Related]
13. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
14. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.
Solomon SD; Zile M; Pieske B; Voors A; Shah A; Kraigher-Krainer E; Shi V; Bransford T; Takeuchi M; Gong J; Lefkowitz M; Packer M; McMurray JJ;
Lancet; 2012 Oct; 380(9851):1387-95. PubMed ID: 22932717
[TBL] [Abstract][Full Text] [Related]
15. LCZ696 : a new paradigm for the treatment of heart failure?
Minguet J; Sutton G; Ferrero C; Gomez T; Bramlage P
Expert Opin Pharmacother; 2015 Feb; 16(3):435-46. PubMed ID: 25597387
[TBL] [Abstract][Full Text] [Related]
16. The Role of Neprilysin Inhibitors in Cardiovascular Disease.
Mills J; Vardeny O
Curr Heart Fail Rep; 2015 Dec; 12(6):389-94. PubMed ID: 26466607
[TBL] [Abstract][Full Text] [Related]
17. The Combination of Valsartan and Sacubitril in the Treatment of Hypertension and Heart Failure - an Update.
Nielsen PM; Grimm D; Wehland M; Simonsen U; Krüger M
Basic Clin Pharmacol Toxicol; 2018 Jan; 122(1):9-18. PubMed ID: 28944989
[TBL] [Abstract][Full Text] [Related]
18. A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Nguyen E; Weeda ER; White CM
J Clin Pharmacol; 2016 Aug; 56(8):936-47. PubMed ID: 26626162
[TBL] [Abstract][Full Text] [Related]
19. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.
Braunwald E
J Am Coll Cardiol; 2015 Mar; 65(10):1029-41. PubMed ID: 25766951
[TBL] [Abstract][Full Text] [Related]
20. First-in-class angiotensin receptor neprilysin inhibitor in heart failure.
Vardeny O; Tacheny T; Solomon SD
Clin Pharmacol Ther; 2013 Oct; 94(4):445-8. PubMed ID: 23872864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]